Synopsis: Park Medi World Limited (PARKHOSPS) reported its strongest financial year to date, with Q4 net profit surging 47% YoY to Rs. 76.8 Crore. Despite record-breaking annual revenue and a massive capacity expansion to nearly 4,000 beds, the stock faced profit-booking in a weak market, declining 5% during Tuesday’s session.
In a regulatory filing submitted to the NSE and BSE, Park Medi World Limited, North India’s second-largest hospital chain, announced its audited financial results for the quarter and year ended March 31, 2026. The company delivered a stellar performance, with Q4 revenue jumping 30% YoY to Rs.460.4 crore. The bottom line followed suit as net profit climbed to Rs. 76.8 crore, supported by a significant EBITDA margin expansion of 268 bps to reach 27.7%.
The full-year (12M FY’26) metrics were equally historic for the group. Park Group recorded its highest-ever annual revenue of Rs. 1,679.4 crore, a 21% increase over the previous fiscal. Net profit for the year rose 27% to Rs. 273.6 crore with profit margins expanding to 16.3%. Management highlighted that FY’26 was a landmark year characterized by simultaneous growth, profitability, and aggressive capacity expansion. The company’s balance sheet remains robust with negligible term bank debt of just Rs. 28.2 crore and strong liquidity, including Rs. 314.1 crore in fixed deposits.
Another key operational highlight was the improvement in working capital efficiency. The company successfully reduced its debtor days from 161 days in March 2025 to 129 days by March 2026, reflecting significantly faster collections from insurance providers and patients. Cash generation also remained strong, with Rs. 329.1 crore generated from operating activities during FY26. Including other balances, total cash and cash equivalents stood at a healthy Rs. 550.9 crore, further strengthening the group’s liquidity position.
Operationally, the year saw a 20% capacity addition as the group added 610 beds through strategic acquisitions in Bhatinda and Agra. Following the recent commissioning of its largest greenfield hospital in Panchkula, the company’s total bed capacity has reached 3,960 beds. Looking ahead, the group is executing an additional 1,500-bed capacity across five hospitals slated for completion by FY’28.
Commenting on the results, Chairman Dr. Ajit Gupta and Managing Director Dr. Ankit Gupta described FY26 as the “finest year in Park Medi World’s history.” The leadership emphasized that the immediate strategic focus will be on seamlessly integrating the recently acquired hospital assets and improving utilization levels across these newer facilities to drive the next phase of growth.
Despite delivering record-breaking results, shares of Park Medi World Limited faced notable profit-booking pressure as the broader NIFTY 50 Index declined by more than 1.5%. As of 2:14 PM on May 12, 2026, the stock was trading at ₹246.88, down 5.05% from its previous close. Earlier in the session, it had surged to a fresh 52-week high of ₹266.80 before witnessing an intraday reversal.
As of May 12, 2026, the company’s market capitalization stands at approximately Rs.10,657.03 crore. Since its listing in December 2025, the stock has emerged as one of the standout performers in the NIFTY IPO Index, delivering an impressive year-to-date return of 64.60%. Market analysts believe the current pullback reflects broader market volatility rather than any deterioration in fundamentals, particularly with a healthy deliverable quantity of 38.12% recorded in today’s trades.
Company Overview
Park Medi World Limited, operating as the Park Group of Hospitals, is North India’s 2nd largest hospital chain. The group operates 16 hospitals across 14 cities, including Delhi, Gurugram, and Jaipur, serving millions with multi-superspeciality care. Founded on a commitment to affordable, high-quality healthcare, the group offers services spanning cardiology, oncology, organ transplants, and advanced diagnostics.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor.
